促销时间表 Marinus Pharmaceuticals, Inc.
先进的时间表
简单图表
关于公司
Фармацевтическая компания Marinus Pharmaceuticals, Inc. занимается разработкой и коммерциализацией терапевтических продуктов для пациентов, страдающих редкими генетическими эпилепсиями и другими судорожными расстройствами. Он предлагает ZTALMY (ганаксолон), пероральную суспензию для лечения судорог, связанных с синдромом дефицита циклинзависимой киназы 5, для взрослых и детей, находящихся в неотложной и хронической помощи, а также в стационарных условиях и в условиях самостоятельного приема.
更多详情| Выручка | 0.0017 |
|---|---|
| EBITDA | -0.0541 |
| P/S | 193.65 |
| EV/EBITDA | -0.3523 |
| Цена ао | 1.35 |
| P/BV | 1.25 |
| Сайт | https://marinuspharma.com |
| ISIN | US56854Q2003 |
| Число акций ао | 0.05375 млрд |
| Валюта | usd |
| IPO date | 2014-07-31 |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Валюта отчета | usd |
| 每日价格变化: | 0% (1.75) |
|---|---|
| 每周价格变化: | -5.41% (1.85) |
| 每月价格变化: | +16.67% (1.5) |
| 3个月内价格变化: | +18.64% (1.475) |
| 六个月内的价格变化: | +21.53% (1.44) |
| 每年价格变化: | -74.26% (6.8) |
| 3年内价格变化: | -84.66% (11.41) |
| 5年内价格变化: | -2.78% (1.8) |
| 年初以来价格变化: | -71.59% (6.16) |
|
|
低估
|
效率
|
|||||||||||||||||||||||||||||||||||||
股息
|
责任
|
成长冲动
|
|||||||||||||||||||||||||||||||||||||
| 交易日期 | 披露日期 | 内幕 | 类型 | 价格 | 体积 | 数量 | 分享最多, % | 之后分享, % | 文档 |
|---|---|---|---|---|---|---|---|---|---|
| 05.08.2024 | 07.08.2024 | Braunstein Scott CHAIRMAN AND CEO |
销售 | 1.13 | 13 724 | 12145 | 0 | -0.03 | 关联 |
| 05.08.2024 | 07.08.2024 | Hulihan Joseph CHIEF MEDICAL OFFICER |
销售 | 1.13 | 5 456 | 4828 | 0 | -0.01 | 关联 |
| 05.08.2024 | 07.08.2024 | MANNING MARTHA E SVP, GEN. COUNSEL & CORP. SEC. |
销售 | 1.13 | 4 092 | 3621 | 0 | -0.01 | 关联 |
| 05.08.2024 | 07.08.2024 | Shafer Christina CHIEF COMMERCIAL OFFICER |
销售 | 1.14 | 4 355 | 3820 | 0 | -0.01 | 关联 |
| 05.08.2024 | 07.08.2024 | Pfanstiel Steven CFO AND COO |
销售 | 1.13 | 5 262 | 4657 | 0 | -0.01 | 关联 |
| 机构 | 体积 | 分享, % |
|---|---|---|
| Suvretta Capital Management, LLC | 4831261 | 9.56 |
| Eventide Asset Management LLC | 3173197 | 6.28 |
| Point72 Asset Management, L.P. | 3153000 | 6.24 |
| Avoro Capital Advisors LLC | 3150000 | 6.23 |
| Lion Point Capital, LP | 2620096 | 5.18 |
| Vanguard Group Inc | 2184744 | 4.32 |
| Adage Capital Partners GP L.L.C. | 2034500 | 4.02 |
| Bleichroeder LP | 1872463 | 3.7 |
| Jennison Associates LLC | 1865430 | 3.69 |
| Woodline Partners LP | 1597411 | 3.16 |
| ETF | 分享, % | 本年盈利能力, % | 股息, % |
|---|---|---|---|
| ProShares Ultra Nasdaq Biotechnology | 0.00551 | 51.697637072723 | 0.85651 |
| Invesco Nasdaq Biotechnology ETF | 0.00847 | 28.578975171685 | 0.8565 |
| iShares Micro-Cap ETF | 0.02323 | 36.318555985322 | 1.54048 |
| Principal Healthcare Innovators ETF | 0.00835 | 618.4964157054 | 0.8416 |
| Future Tech ETF | 0.00835 | 426.33969118983 | 0.8416 |
| 导师 | 职称 | 支付 | 出生年份 |
|---|---|---|---|
| Dr. Scott N. Braunstein M.D. | CEO, President & Chairman | 919.29k | 1963 (61 年) |
| Mr. Steven E. Pfanstiel C.M.A., M.B.A. | COO, CFO & Treasurer | 580.35k | 1973 (51 年) |
| Dr. Joseph Hulihan M.D. | Chief Medical Officer | 639.51k | 1957 (67 年) |
| Dr. Alex Aimetti Ph.D. | Chief Scientific Officer | N/A | |
| Ms. Sonya Weigle | Senior VP of Investor Relations, Human Resources & Corporate Affairs | N/A | |
| Ms. Martha E. Manning Esq., J. D. | Senior VP, General Counsel & Secretary | N/A | 1955 (69 年) |
| Molly Cameron | Director of Corporate Communications & Investor Relations | N/A | |
| Dr. Kimberly A. McCormick Pharm.D. | Chief Regulatory & Quality Assurance Officer | N/A | |
| Ms. Christina Shafer | Chief Commercial Officer | N/A | 1977 (47 年) |
| Mr. David Czekai | Chief Chemistry, Manufacturing & Controls Officer |
地址: United States, Radnor. PA, 5 Radnor Corporate Center - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://marinuspharma.com
网站: https://marinuspharma.com
